By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intarcia Therapeutics, Inc. 

155 Seaport Boulevard
11th Floor
Boston  Massachusetts  02210  U.S.A.
Phone: 617-936-2500 Fax: n/a


Key Statistics

Ownership: Private

Web Site: Intarcia


Drug Discovery

Company News
Intarcia CEO Kurt Graves Discusses Phoundry Acquisition and Future of Diabetes Treatment 9/30/2015 12:47:09 PM
Intarcia Buys One Month Old Startup Phoundry 9/24/2015 11:26:27 AM
Intarcia Presents Results From Two Successful Phase 3 Trials For ITCA 650, Its Investigational Therapy In Type 2 Diabetes, At 51st EASD 9/16/2015 10:31:43 AM
Intarcia Announces New Top-Line Phase III Results For Investigational Therapy ITCA 650 In Type 2 Diabetes 8/19/2015 8:14:26 AM
Intarcia Diabetes Implant Beats Merck & Co. (MRK)'s $6 Billion Drug in Head-to-Head Study 8/19/2015 6:38:22 AM
Intarcia Announces Presentations At American Diabetes Association Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes 6/8/2015 10:06:37 AM
Intarcia 's Kurt Graves Named An EY Entrepreneur Of The Year 2015 6/8/2015 7:22:25 AM
Intarcia To Announce Key ITCA 650 Phase 3 Findings And Other Data Presentations At Upcoming 75th Scientific Sessions Of The American Diabetes Association In Boston 6/3/2015 11:15:10 AM
Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 6/2/2015 1:58:07 PM
Intarcia Names Emad Rizk, MD, To Board Of Directors 5/19/2015 11:01:12 AM